Expertise in
32
conditions

Dr. Prithviraj Bose

Hematology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Offers Telehealth
Expertise in
32
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Prithviraj Bose is a Hematologist in Cary, North Carolina. Dr. Bose is highly rated in 32 conditions, according to our data. His top areas of expertise are Myelofibrosis, Essential Thrombocythemia, Myeloproliferative Neoplasms (MPN), Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 228 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Patients With Myelofibrosis
A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Patients With Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2026
Intervention Type: Other, Biological
Study Drug: Elotuzumab
Study Phase: Phase 2
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Other, Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)
PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: IFN-alpha2a
Study Phase: Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 2
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 1
A Phase II Study of Isavuconazole Prophylaxis in Adult Patients With AML/MDS and Neutropenia
A Phase II Study of Isavuconazole Prophylaxis in Adult Patients With AML/MDS and Neutropenia
Enrollment Status: Completed
Publish Date: October 26, 2021
Intervention Type: Drug
Study Phase: Phase 2
Alternating or Combined Therapy With Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated, or Blastic Phases
Alternating or Combined Therapy With Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated, or Blastic Phases
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug, Other
Study Phase: Phase 1
View 10 Less Clinical Trials

228 Total Publications

Current treatments, practical management, and emerging investigational therapies for myelofibrosis.
Current treatments, practical management, and emerging investigational therapies for myelofibrosis.
Journal: Expert review of hematology
Published: December 14, 2025
Similar Doctors
Expertise in
39
conditions
Dr. Tapan Kadia
Hematology
Expertise in
39
conditions
Dr. Tapan Kadia
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.9 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist in Cary, North Carolina. Dr. Kadia is highly rated in 39 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Prolymphocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Richard Champlin
Expertise in
30
conditions
Dr. Richard Champlin
Hematology
Expertise in
30
conditions
Dr. Richard Champlin
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.9 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Richard Champlin is a Hematologist in Cary, North Carolina. Dr. Champlin is highly rated in 30 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
23
conditions
Dr. Paolo Strati
Hematology
Expertise in
23
conditions
Dr. Paolo Strati
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.9 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paolo Strati is a primary care provider, practicing in Hematologist in Cary, North Carolina. Dr. Strati is highly rated in 23 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Prithviraj Bose

How do I make an appointment with Dr. Prithviraj Bose?

You can book an appointment with Dr. Prithviraj Bose by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Prithviraj Bose a top-rated expert for Myelofibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Prithviraj Bose is classified as an Elite expert for Myelofibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Prithviraj Bose specialize in?

While Dr. Prithviraj Bose is a Hematology, they have specific expertise in Myelofibrosis, Essential Thrombocythemia, and Myeloproliferative Neoplasms (MPN). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Prithviraj Bose participate in research or clinical trials?

Yes. Dr. Prithviraj Bose has published 228 articles and abstracts on conditions like Myelofibrosis. You can view a list of Dr. Prithviraj Bose's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Prithviraj Bose accept my insurance?

Dr. Prithviraj Bose accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bose's expertise for a condition
ConditionClose
View All 11 Elite Conditions
View All 11 Distinguished Conditions
View All 10 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile